Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
XVIVO Stock Chart & Stats
kr192.70
-kr5.00(-1.20%)
At close: 4:00 PM EST
kr192.70
-kr5.00(-1.20%)
Day’s Range― - ―
52-Week Rangekr160.00 - kr338.00
Previous CloseN/A
Volume6.25K
Average Volume (3M)168.41K
Market Cap
kr7.12B
Enterprise Valuekr7.06B
Total Cash (Recent Filing)kr292.09M
Total Debt (Recent Filing)kr237.89M
Price to Earnings (P/E)233.6
Beta1.18
Next Earnings
Apr 24, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.04
Shares Outstanding31,499,470
10 Day Avg. Volume158,765
30 Day Avg. Volume168,408
Financial Highlights & Ratios
PEG Ratio-2.74
Price to Book (P/B)2.78
Price to Sales (P/S)7.24
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.9
Revenue Forecast (FY)kr975.15M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageLow leverage and a sizable equity cushion give XVIVO durable financial flexibility to fund commercialization and production scaling. A stronger balance sheet reduces refinancing risk, supports capex for capacity expansion and absorbs execution delays without immediate reliance on dilutive financing.
Leading Clinical Adoption And Liver MomentumClinical superiority data, published long‑term outcomes and meaningful EU penetration create a structural competitive edge for liver products. FDA breakthrough status and international approvals shorten regulatory pathways and underpin durable consumable demand and higher switching costs for transplant centers.
Production Scale-up To Support Consumables GrowthA planned ~10x disposable capacity expansion addresses manufacturing bottlenecks and enables sustainable consumable pull‑through as installed base grows. Scaling lowers unit costs, improves gross margin sustainability, and positions the company to capture recurring revenue from increased transplant volumes.
Bears Say
Inconsistent Cash Conversion And FCF VolatilityUneven cash conversion and episodic negative free cash flow limit XVIVO's ability to self‑fund growth and increase reliance on external capital for launches and capacity buildouts. This makes multi‑quarter execution and working‑capital management critical to sustain investments without diluting shareholders.
Regulatory Timing And Pathway UncertaintyUncertain regulatory timelines for heart and liver products can materially delay U.S. commercialization and revenue recognition. Shifting pathways (paused PMA) raise execution risk, extend time to market and increase development costs, making near‑term scaling outcomes more contingent on regulatory progress.
Services Weakness And U.S. Field‑execution GapsDeclining Services revenue and low margins weaken recurring annuity income and limit customer support for EVLP and organ‑recovery models. Rebuilding services requires time and hires/partnerships; prolonged underperformance would reduce lifetime revenue per customer and pressure overall margin sustainability.
Xvivo Perfusion AB News
XVIVO FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.00 and its highest was kr338.00 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is kr7.12B.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Apr 24, 2026 which is in 28 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Jan 27, 2026. The company reported kr1.045 earnings per share for the quarter, beating the consensus estimate of kr0.684 by kr0.361.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB does not currently pay dividends.
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.65.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of kr1.045 in its last earnings report, beating expectations of kr0.684. Following the earnings report the stock price went up 3.565%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in SE:XVIVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
XVIVO Company Deck
XVIVO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong, company-defining positives: record quarterly EBITDA, first positive quarter cash flow, meaningful growth and market penetration in abdominal and liver segments, significant clinical milestones for Heart Assist (including a 76% reduction in severe PGD) and expanding EVLP service models. However, meaningful near-term challenges were also highlighted: weakness in Services, inventory write-offs depressing margins, earlier-than-expected EVLP shortfalls due to U.S. field force gaps, regulatory timing uncertainty, and currency risks. The company is taking corrective actions (hiring, partnerships, scaling production) and plans heavy investments in 2026 to support launches and future growth. On balance the clinical breakthroughs, record profitability metrics for Q4, and operational scaling progress outweigh the operational and timing challenges, but the near-term path will include planned investments and execution risk.View all SE:XVIVO earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---